1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.
Voor meer informatie: http://www.quirem.com/
![1st production QuiremSpheres](https://radboudtranslationalmedicine.nl/cdn/7bc02248-6fd7-49f7-9804-02f59c60fcef/-/resize/555x/-/format/auto/-/quality/smart/transport.jpg)
Other news
![GMP-certificate received](https://radboudtranslationalmedicine.nl/cdn/d8e82eeb-ebb5-4876-a874-f2bd22bd1425/-/crop/433x294/7,-14/-/smart_resize/250x170/-/scale_crop/250x170/smart/-/format/auto/-/quality/smart/logo-igz.png)
GMP-certificate received
Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...
![First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer](https://radboudtranslationalmedicine.nl/cdn/6bac4557-a1f4-4d63-9b07-9644f2141bfa/-/smart_resize/250x170/-/format/auto/-/quality/smart/telix-nieuwsbericht.jpg)
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
![Upcoming event](https://radboudtranslationalmedicine.nl/cdn/72adb851-49a0-43fb-8ffa-b95d16cae731/-/smart_resize/250x170/-/format/auto/-/quality/smart/eanm2016-360x203.jpg)
Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...
![First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer](https://radboudtranslationalmedicine.nl/cdn/6bac4557-a1f4-4d63-9b07-9644f2141bfa/-/smart_resize/250x170/-/format/auto/-/quality/smart/telix-nieuwsbericht.jpg)
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Interested in a collaboration?
Contact us to discuss the possibilities.